Towards a multidimensional scientific approach to improve clinical practices for infertility treatment

Zhu, Yuhang; Qu, Fan

doi:10.1631/jzus.b1801014

Cited by 4 publications

(2 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, the participant's energy consumption and physical activity were not examined; nevertheless, energy intake and physical activity are significant factors influencing body weight, and no data on these variables were reported at baseline and the conclusion of the research [30]. Therefore, metabolic profile abnormalities are prevalent in obese adolescents [44]. Lastly, Liraglutide side effects, particularly nausea and vomiting, may have caused weight loss [45].…”

Section: Discussionmentioning

confidence: 99%

Efficacy of Liraglutide in Obesity in Children and Adolescents: Systematic Review and Meta-Analysis of Randomized Controlled Trials

et al. 2023

View full text Add to dashboard Cite

In the past few decades, childhood obesity has become a significant global health issue, impacting around 107.7 million children and adolescents globally. There is currently minimal usage of pharmacological therapies for childhood obesity in the pediatric population. This research assessed the efficacy of liraglutide in treating childhood and adolescent obesity. Until 20 October 2022, a systematic literature review was done utilizing PubMed, Scopus, Web of Science, and Embase databases. The search phrases “liraglutide”, “pediatric obesity”, “children”, and “adolescents” were utilized. Using the search method, a total of 185 articles were found. Three studies demonstrating liraglutide’s effectiveness in treating child and adolescent obesity were included. The selected research was done in the United States. As an intervention, liraglutide was administered to 296 participants at a maximal dosage of 3.0 mg. All examined trials were in phase 3. This comprehensive analysis revealed no clinically significant differences between liraglutide and body weight (kg; MD −2.62; 95%CI −6.35 to 1.12; p = 0.17) and body mass index (kg/m2; MD −0.80; 95%CI −2.33 to 0.73, p = 0.31). There was no evidence that liraglutide increased hypoglycemia episodes (RR 1.08; 95%CI 0.37 to 3.15; p = 0.79), or side consequences. However, it was shown that the medicine might help reduce BMI and weight combined with a healthy diet and regular exercise. A lifestyle change may have favorable consequences that will be assessed in the future for adjunctive therapy. PROSPERO database (CRD42022347472)

show abstract

Section: Discussionmentioning

confidence: 99%

Efficacy of Liraglutide in Obesity in Children and Adolescents: Systematic Review and Meta-Analysis of Randomized Controlled Trials

et al. 2023

View full text Add to dashboard Cite

show abstract

“…PCOS is the leading cause of sub-fecundity and anovulatory infertility (Pan et al, 2018;Zhu and Qu, 2018). Even if being pregnant, women with PCOS have an increased prevalence of pregnancy complications, which may result in a compromised pregnancy and offspring outcomes (Palomba et al, 2015).…”

Section: Introductionmentioning

confidence: 99%

Fetal growth, fetal development, and placental features in women with polycystic ovary syndrome: analysis based on fetal and placental magnetic resonance imaging

Zhang

Bao

Deng

et al. 2020

J. Zhejiang Univ. Sci. B

Self Cite

View full text Add to dashboard Cite

Objective: Polycystic ovary syndrome (PCOS), a common endocrine-metabolic dysfunction in reproductiveaged women, may be involved in compromised pregnancy and offspring outcomes. This study aimed to investigate whether maternal PCOS affects fetal growth, fetal development, and placental features. Methods: This retrospective case-control study included 60 pregnant women with PCOS (PCOS group) and 120 healthy pregnant women without PCOS (control group). Fetal magnetic resonance imaging (MRI) was performed followed by an ultrasound examination and indications for imaging, including known or suspected fetal pathology, history of fetal abnormality in previous pregnancy or in a family member, and concern for placenta accreta. Fetal MRI images were analyzed for head circumference (HC), abdomen circumference (AC), lung-to-liver signal intensity ratio (LLSIR, a prenatal marker of fetal lung maturity), lengths of liver and kidney diameters in fetuses, and placental relative signal intensity on T2-weighted single-shot fast spin echo (SSFSE) imaging (rSI SSFSE ), and placental relative apparent diffusion coefficient value (rADC). Data on height and weight of offspring were collected through telephone follow-up. Results: Compared to the control group, the PCOS group showed the following characteristics: (1) smaller biparietal diameter and femur length in fetuses (P=0.026 and P=0.005, respectively), (2) smaller HC in fetuses (evident after 32 weeks; P=0.044), (3) lower LLSIR and smaller dorsoventral length of liver in fetuses (evident before 32 weeks; P=0.005 and P=0.019, respectively), and (4) smaller placental thickness (evident before 32 weeks; P=0.017). No significant differences in placental rSI SSFSE or rADC were observed between the groups (all P>0.05). No significant differences in height and weight of offspring during childhood existed between the groups (all P>0.05). Conclusions: There exist alterations of fetal growth, fetal development, and placental features from women with PCOS.

show abstract

Association between maternal polycystic ovary syndrome and early childhood growth: a continuous observation from 3 months to 6 years of age

Zhang

Ying

Zhang

et al. 2022

J Assist Reprod Genet

View full text Add to dashboard Cite

Towards a multidimensional scientific approach to improve clinical practices for infertility treatment

Cited by 4 publications

References 15 publications

Efficacy of Liraglutide in Obesity in Children and Adolescents: Systematic Review and Meta-Analysis of Randomized Controlled Trials

Efficacy of Liraglutide in Obesity in Children and Adolescents: Systematic Review and Meta-Analysis of Randomized Controlled Trials

Fetal growth, fetal development, and placental features in women with polycystic ovary syndrome: analysis based on fetal and placental magnetic resonance imaging

Association between maternal polycystic ovary syndrome and early childhood growth: a continuous observation from 3 months to 6 years of age

Contact Info

Product

Resources

About